Form 8-K

8-K — Citius Pharmaceuticals, Inc.

Accession: 0001213900-26-053916

Filed: 2026-05-08

Period: 2026-05-04

CIK: 0001506251

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Entry into a Material Definitive Agreement

Item: Financial Statements and Exhibits

Documents

8-K — ea0289731-8k_citius.htm (Primary)

EX-10.1 — THIRD AMENDMENT TO PROMISSORY NOTE, DATED AS OF MAY 4, 2026, BETWEEN THE COMPANY AND CITIUS ONCOLOGY (ea028973101ex10-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0289731-8k_citius.htm · Sequence: 1

false

0001506251

2026-05-04

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

May 4, 2026

Citius Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Nevada

(State or other jurisdiction of incorporation)

001-38174

27-3425913

(Commission File Number)

(IRS Employer

Identification No.)

11 Commerce Drive, 1st Floor, Cranford, NJ

07016

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including

area code (908) 967-6677

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b)

of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, $0.001 par value

CTXR

The Nasdaq Capital Market

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01. Entry into a Material Definitive Agreement.

On May 4, 2026, in connection

with an equity financing transaction and debt facility by Citius Oncology, Inc. (“Citius Oncology”), the majority-owned subsidiary

of Citius Pharmaceuticals, Inc. (the “Company”), the Company and Citius Oncology entered into a Third Amendment to Promissory

Note (the “Third Amendment”), which amends the promissory note, dated August 16, 2024, as previously amended on September

10, 2025 and December 10, 2025, issued by the Citius Oncology to the Company in the original principal amount of $3,800,111 (the “Promissory

Note”), to, among other things, (i) conform the payment and maturity provisions of the Promissory Note to the subordination agreement

entered into by Citius Oncology in connection with its debt facility, such that the entire unpaid principal balance of the Promissory

Note shall be payable on a date that is 91 days after the senior debt of Citius Oncology has been fully paid and the related loan and

security agreement has been terminated, (ii) eliminate all prior maturity triggers related to capital raises, issuances of debt or equity

securities, or royalty-backed monetizations, (iii) prohibit prepayment of the Promissory Note in cash prior to the new maturity date,

and (iv) add a voluntary conversion feature allowing the Company, subject to Citius Oncology’s approval, to convert all or a portion

of the outstanding principal into shares of common stock at a conversion price equal to $0.90 per share. All other terms of the Promissory

Note remain the same.

The foregoing description

of the Third Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Third Amendment,

which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) The following exhibits are being

filed with this Current Report on Form 8-K.

Exhibit

Description

10.1

Third Amendment to Promissory Note, dated as of May 4, 2026, between the Company and Citius Oncology.

104

Cover Page Interactive Date File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements

of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto

duly authorized.

CITIUS PHARMACEUTICALS, INC.

Date: May 8, 2026

/s/ Leonard Mazur

Leonard Mazur

Chairman and Chief Executive Officer

EX-10.1 — THIRD AMENDMENT TO PROMISSORY NOTE, DATED AS OF MAY 4, 2026, BETWEEN THE COMPANY AND CITIUS ONCOLOGY

EX-10.1

Filename: ea028973101ex10-1.htm · Sequence: 2

Exhibit 10.1

THIRD AMENDMENT TO PROMISSORY NOTE

This THIRD AMENDMENT TO

PROMISSORY NOTE (this “Amendment”), dated as of May 4, 2026, is entered into by and between CITIUS ONCOLOGY,

INC., a Delaware corporation (“Payor”), and CITIUS PHARMACEUTICALS, INC., a Nevada corporation (“Payee”).

R E C I T A L S

A. Payor

executed and delivered to Payee that certain Promissory Note dated August 16, 2024, in the original principal amount of $3,800,111, as

amended on September 10, 2025 and December 10, 2025 (as amended, restated, supplemented or otherwise modified from time to time, the “Note”).

B. Payee

and AVENUE VENTURE OPPORTUNITIES FUND II, L.P., a Delaware limited partnership, as administrative agent and collateral agent (in such

capacities, including any successors and assigns, “Agent”) for the benefit of itself and Lenders (as defined

in the Subordination Agreement), shall enter into a subordination agreement substantially in the form set forth in Exhibit A hereto

(as amended, restated, supplemented or otherwise modified from time to time, the “Subordination Agreement”),

pursuant to which the indebtedness evidenced by the Note is subordinated to the Senior Debt (as defined in the Subordination Agreement).

C. Payor

and Payee desire to amend the Note to, among other things, conform the payment and maturity provisions of the Note to the Subordination

Agreement and to confirm their respective obligations thereunder.

NOW, THEREFORE, in consideration

of the mutual covenants and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of

which are hereby acknowledged, Payor and Payee hereby agree as follows:

1. Defined Terms

Capitalized terms used in this Amendment and not

otherwise defined herein have the meanings assigned to them in the Note (as amended by this Amendment). In addition, the following new

Section 13 is hereby inserted into the Note:

“13. Definitions. As used in this Note, the following capitalized terms have the following meanings:

(a) “Third Amendment Agreement” means that certain Third Amendment to Promissory

Note dated as of May 4, 2026 by and between Payor and Payee.

(b) “Loan Agreement” has the meaning assigned to such term in the Subordination

Agreement.

date on which each of the following conditions has been satisfied: (i) the Senior Debt has been indefeasibly paid in full in cash; (ii)

no Senior Lender has any further commitment or obligation to extend credit to Payor; and (iii) the Loan Agreement has been terminated

in accordance with its terms; provided, however, that if the Loan Agreement and/or the Subordination Agreement has not been

executed as of any date of determination, the Maturity Date shall not occur until ninety-one (91) days after the first date on which all

of the foregoing conditions have been satisfied after the execution of the Loan Agreement and the Subordination Agreement.

(d) “Senior Agent” has the meaning assigned to the term “Agent” in the

Third Amendment Agreement.

(e) “Senior Debt” has the meaning assigned to such term in the Subordination Agreement.

(f) “Senior Lender” has the meaning assigned to the term “Lender” in

the Subordination Agreement.

(g) “Standstill Period” means the period beginning on the date of the Third Amendment

Agreement and continuing through the Maturity Date.

(h) “Subordination Agreement” has the meaning assigned to such term in the Third

Amendment Agreement.”

2. Amendment to Section 1 (Principal) of the Note

Section 1 of the Note is hereby deleted in its

entirety and replaced with the following:

“1. Principal.

The entire unpaid principal balance of this Note shall be payable on the Maturity Date. The principal balance may not be prepaid in

cash prior to the Maturity Date. Under no circumstances shall any individual, including but not limited to any officer, director, employee

or shareholder of Payor, be obligated personally for any obligations or liabilities of Payor hereunder.”

All references in the Note to the obligations

thereunder becoming due upon the completion of any capital raise, the issuance of debt or equity securities, or any royalty-backed monetization

of LYMPHIR (or any analogous trigger based on such events) are hereby deleted and shall be of no further force or effect.

For the avoidance of doubt, neither the closing

of any debt or equity financing by Payor nor any royalty-backed monetization of LYMPHIR shall, in and of itself, cause any principal of,

interest on, or other amounts owing under the Note to become due and payable before the Maturity Date.

3. The following new Section 12 is hereby inserted into the Note:

“12. Conversion.

a) Voluntary

Conversion. Notwithstanding anything herein to the contrary, at any time and from time to time, commencing on the date of this Amendment

until this Note is no longer outstanding, this Note shall be convertible, in whole or in part, into shares of common stock, par value

$0.0001 per share (the “Common Stock”), at the option of Payee, subject to the approval of Payor. Payee shall

effect a conversion by delivering to Payor a notice of conversion (each, a “Notice of Conversion”), specifying

therein the principal amount of this Note to be converted and the date on which such conversion shall be effected (such date, the “Conversion

Date”). Conversions hereunder shall have the effect of lowering the outstanding principal amount of this Note in an amount

equal to the applicable conversion amount.

b) Conversion

Price. The conversion price in effect on any Conversion Date shall be equal to $0.90 (the “Conversion Price”).

The Conversion Price will be appropriately adjusted for any stock dividend, stock split, stock combination, reclassification or similar

transaction that proportionately decreases or increases the Common Stock during such measuring period.

c) Mechanics

of Conversion.

i. Conversion

Shares Issuable Upon a Conversion. The number of shares of Common Stock issuable upon a conversion hereunder shall be determined by

the quotient obtained by dividing (x) the outstanding principal to be converted as provided in the applicable Notice of Conversion by

(y) the Conversion Price (the “Conversion Shares”).

ii. Delivery

of Certificate Upon Conversion. Not later than two (2) Trading Days after each Conversion Date (the “Share Delivery Date”),

Payor shall deliver, or cause to be delivered, to Payee a certificate representing the number of Conversion Shares being acquired upon

the conversion of this Note. All certificates required to be delivered by Payor under this Section 12(c) shall be delivered electronically

through DTC or another established clearing corporation performing similar functions, unless Payor or its Transfer Agent does not have

an account with DTC and/or is not participating in the DTC/FAST System, in which case Payor shall issue and deliver to the address as

specified in such Notice of Conversion a certificate registered in the name of Payee or its designee for the number of Conversion Shares

to which Payee shall be entitled. The Conversion Shares shall bear a restrictive legend in the following form, as appropriate:

“THE ISSUANCE AND SALE OF

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE

SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE

REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL ACCEPTABLE TO THE

COMPANY THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT.”

iii. Fractional

Shares. No fractional shares or scrip representing fractional shares shall be issued upon the conversion of this Note. As to any fraction

of a share that Payee would otherwise be entitled to purchase upon such conversion, Payor shall round down to the next whole share.

iv. Transfer

Taxes and Expenses. The issuance of certificates for shares of the Common Stock on conversion of this Note shall be made without charge

to Payee hereof for any documentary stamp or similar taxes that may be payable in respect of the issue or delivery of such certificates.”

4. Acknowledgment of Subordination and Payment Standstill

Payor and Payee acknowledge and agree that the

Note and all obligations evidenced thereby are and shall remain subject and subordinate in all respects to the Senior Debt and to the

terms and conditions of the Subordination Agreement.

(a) During

any Standstill Period, Payee shall not demand, sue for, accelerate, collect, accept or receive any payment or distribution on account

of the Note in cash, or otherwise exercise any remedies with respect to the Note, except in each case to the extent expressly permitted

under the Subordination Agreement.

(b) During

any Standstill Period, Payor shall not make, and Payee shall not accept, any payment or distribution on account of the Note in cash, except

to the extent expressly permitted under the Subordination Agreement.

the event of any conflict between the terms of the Note (as amended hereby) and the terms of the Subordination Agreement, the terms of

the Subordination Agreement shall control.

5. No Default; Note Remains Outstanding

(a) Notwithstanding

anything to the contrary in the Note, no failure by Payor to make any payment on account of the Note during any Standstill Period shall

constitute a default, event of default, breach or cause for acceleration under the Note.

(b) The

Note and the indebtedness evidenced thereby shall remain outstanding until paid in full in accordance with the Note, as amended by this

Amendment, and the Subordination Agreement, and shall not be deemed satisfied, discharged, novated or otherwise extinguished by reason

of any capital raise, any royalty-backed monetization of LYMPHIR, or the occurrence of any event that would have constituted a maturity

trigger under the Note before giving effect to this Amendment.

6. Further Conforming Changes

Any right of Payee under the Note to declare the

obligations thereunder immediately due and payable, or to take any enforcement action with respect thereto, shall in all respects be subject

to the Subordination Agreement and any applicable Standstill Period. All notices, demands and payment obligations under the Note shall

be construed consistently with this Amendment.

7. Reaffirmation; No Other Amendments

Except as expressly amended by this Amendment,

the Note remains unmodified and in full force and effect. On and after the effective date of this Amendment, each reference in the Note

to “this Note,” “hereof,” “hereunder” or words of similar import shall mean the Note as amended by

this Amendment.

8. Miscellaneous

(a) This

Amendment shall be governed by and construed in accordance with the internal laws of the State of Delaware, without regard to conflicts-of-law

principles.

(b) This

Amendment may be executed in counterparts, each of which shall be deemed an original, and all of which together shall constitute one and

the same instrument.

of an executed signature page of this Amendment by electronic transmission shall be effective as delivery of a manually executed signature

page.

(d) This

Amendment shall constitute a note document for all purposes of the Note and the Subordination Agreement.

[Signature Page Follows]

IN WITNESS WHEREOF, Payor and Payee have executed

this Third Amendment to Promissory Note as of the date first written above.

PAYOR:

PAYEE:

CITIUS ONCOLOGY, INC.

CITIUS PHARMACEUTICALS, INC.

By:

/s/ Leonard Mazur

By:

/s/ Leonard Mazur

Name:

Leonard Mazur

Name:

Leonard Mazur

Title:

Chairman and Chief Executive Officer

Title:

Chairman and Chief Executive Officer

[Signature page to Third Amendment to Promissory

Note]

EXHIBIT A

FORM OF SUBORDINATION AGREEMENT

[Signature page to Third Amendment to Promissory

Note]

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

May 04, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 04, 2026

Entity File Number

001-38174

Entity Registrant Name

Citius Pharmaceuticals, Inc.

Entity Central Index Key

0001506251

Entity Tax Identification Number

27-3425913

Entity Incorporation, State or Country Code

Entity Address, Address Line One

11 Commerce Drive

Entity Address, Address Line Two

1st Floor

Entity Address, City or Town

Cranford

Entity Address, State or Province

Entity Address, Postal Zip Code

07016

City Area Code

908

Local Phone Number

967-6677

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common stock, $0.001 par value

Trading Symbol

CTXR

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration